IGF2BP3 binds to FBXO32 to activate the cyclic guanosine monophosphate-protein kinase G pathway, promoting gastric cancer progression

Figure 1 Increased IGF2BP3 expression is associated with poor prognosis in gastric cancer patients. A-C: Expression of N⁶-methyladenosine-related genes in The Cancer Genome Atlas and the GSE54129 and GSE66229 datasets. Red and blue bars represent expression of IGF2BP3 messenger RNA (mRNA) in gastric cancer (GC) tissue and adjacent normal tissue, respectively; D: Kaplan-Meier analysis of IGF2BP3 expression levels and overall survival in GC patients (the cutoff for high vs low expression groups was defined by the median value of IGF2BP3 expression in the cohort); E: Expression levels of IGF2BP3 mRNA in 50 pairs of GC and adjacent normal tissue samples as detected by quantitative reverse transcription polymerase chain reaction; F: Representative images showing IGF2BP3 protein expression levels in 63 pairs of GC and adjacent normal tissue samples, as detected by immunohistochemical staining. Scale bars: 200 μm and 50 μm. Data are presented as the mean ± SD. ^bP < 0.01. ^dP < 0.0001. HR: Hazard ratio; mRNA: Messenger RNA.